Early diagnosis, treatment intensification essential to improve diabetes outcomes healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
SAN DIEGO — Combination cagrilintide and semaglutide therapy is associated with a 15.6% weight loss and 2.2% reduction in HbA1c among adults with obesity and type 2 diabetes, according to a speaker.In findings from a phase 2a trial that were presented at the American Diabetes Association Scientific Sessions and simultaneously published in The Lancet, 71% of adults receiving coadministered
CagriSema (cagrilintide plus semaglutide) led to weight loss of a magnitude not previously reported with pharmacotherapies in type 2 diabetes, plus improved CGM measures, in a phase 2 trial.
SAN DIEGO — Adults with obesity and type 2 diabetes achieved a 14.7% weight loss at 72 weeks with 15 mg tirzepatide, according to data from the SURMOUNT-2 trial presented at the American Diabetes Association Scientific Sessions.In a phase 3 randomized controlled trial, more than 60% of adults with obesity and type 2 diabetes lost at least 10% of their body weight at 72 weeks if they were